Indications for: OMNIPAQUE ORAL SOLUTION 9
In conjunction with Omnipaque 240 or 300 intravenous injection, for computerized tomography (CT) of the abdomen.
For oral use only. Give all at once or over a period of up to 45mins. 500–1000mL. See full labeling for concomitant Omnipaque 300 IV inj dosing.
For oral use only. Give all at once or over a period of up to 45mins. 180–750mL. Max oral iodine (<3yrs): 5g; (3–18yrs): 10g. See full labeling for concomitant Omnipaque 240 or 300 IV inj dosing.
OMNIPAQUE ORAL SOLUTION 9 Contraindications:
OMNIPAQUE ORAL SOLUTION 9 Warnings/Precautions:
Hemolysis may occur if administered intravascularly. Have emergency treatment and trained personnel readily available. Monitor for hypersensitivity reactions. Thyroid dysfunction (esp. children 0–3yrs); monitor. Ensure adequate hydration. Elderly. Pregnancy. Nursing mothers: consider interrupting; pump/discard breast milk for 10hrs after administration.
OMNIPAQUE ORAL SOLUTION 9 Classification:
Radiographic contrast medium.
OMNIPAQUE ORAL SOLUTION 9 Interactions:
See full labeling. Discontinue metformin at time of, or prior to Omnipaque in patients with eGFR 30–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart metformin if renally stable. Discontinue CNS active drugs (eg, MAOIs, tricyclics, CNS stimulants, analeptics, tranquilizers, antipsychotics) ≥48hrs before myelography and for ≥24hrs post-procedure. Caution with beta-blockers. May interfere with thyroid uptake of radioactive iodine and decrease efficacy in thyroid carcinoma for up to 6–8 weeks. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.
Generic Drug Availability:
Oral soln (500mL)—10